Results 221 to 230 of about 32,890 (266)

Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial

Lancet, The, 2022
BACKGROUND Active-comparator trials are important to inform patient and physician choice. We aimed to evaluate the efficacy and safety of monotherapy with either ustekinumab or adalimumab in biologic-naive patients with moderately to severely active ...
Bruce E Sands, Peter M Irving, Jakob Begun   +2 more
exaly   +2 more sources

Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial

Lancet, The, 2021
BACKGROUND There is an unmet need for a treatment for psoriasis that results in complete skin clearance with a reliably quick response. Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A.
Kristian Reich, Ka Papp, Andrew Blauvelt
exaly   +2 more sources

Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn’s Disease

New England Journal of Medicine
BACKGROUND The efficacy and safety of risankizumab as compared with ustekinumab in patients with Crohn's disease are unknown. METHODS In this phase 3b, multicenter, open-label, randomized, controlled trial with blinded assessment of end points ...
L. Peyrin-Biroulet, J. Chapman, J. Colombel, F. Caprioli, Geert D’Haens, M. Ferrante, Stefan Schreiber, R. Atreya, S. Danese, J. Lindsay, P. Bossuyt, B. Siegmund, Peter M. Irving, R. Panaccione, Qian Cao, E. Neimark, Kori L Wallace, T. Anschutz, K. Kligys, W. Duan, V. Pivorunas, Xiu Huang, S. Berg, Lei Shu, M. Dubinsky   +24 more
exaly   +2 more sources

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials

Lancet, The, 2018
BACKGROUND Risankizumab is a humanised IgG1 monoclonal antibody that binds to the p19 subunit of interleukin-23, inhibiting this key cytokine and its role in psoriatic inflammation. We aimed to assess the efficacy and safety of risankizumab compared with
Kenneth B Gordon, Bruce E Strober, Mark G Lebwohl   +2 more
exaly   +2 more sources

Meta‐analysis: Real‐world effectiveness and safety of ustekinumab in patients with ulcerative colitis

Alimentary Pharmacology and Therapeutics, 2023
Evidence on real‐world outcomes of ustekinumab for ulcerative colitis (UC) patients is needed.
C. Taxonera, D. Olivares, O. N. López-García, C. Alba   +3 more
semanticscholar   +1 more source

Ustekinumab

Hospital Pharmacy, 2010
Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy ...
Dennis J. Cada, Terri L. Levien, Danial E. Baker   +2 more
openaire   +1 more source

Ustekinumab is a promising option for the treatment of postoperative recurrence of Crohn's disease

Journal of Gastroenterology and Hepatology, 2023
Postoperative recurrence (POR) following ileocolonic resection is a major concern in patients with Crohn's disease (CD). The role of ustekinumab (UST) in this setting is poorly known.
F. Macaluso, M. Grova, F. Mocciaro, R. Di Mitri, A. Privitera, M. E. Distefano, A. Vitello, S. Camilleri, C. Ferracane, D. Pluchino, N. Belluardo, E. Giangreco, W. Fries, A. Viola, M. Cappello, L. D'Amato, C. Bertolami, M. Ventimiglia, S. Renna, A. Casà, E. D'Antonio, S. De Vivo, A. Orlando   +22 more
semanticscholar   +1 more source

Safety of vedolizumab and ustekinumab compared with anti-TNF in pregnant women with inflammatory bowel disease.

Clinical Gastroenterology and Hepatology
BACKGROUND AND AIMS Limited data are available on the consequences of prenatal exposure to vedolizumab and ustekinumab. We aimed to compare the safety of vedolizumab and ustekinumab with that of anti-TNF, in pregnant women with inflammatory bowel ...
A. Meyer, Sara Miranda, J. Drouin, Alain Weill, Franck Carbonnel, Rosemary Dray-Spira   +5 more
semanticscholar   +1 more source

Ustekinumab Use in Pediatric Inflammatory Bowel Disease: A French Multicenter Study From the Pediatric GETAID

Journal of Pediatric Gastroenterology and Nutrition - JPGN, 2023
Objectives: Ustekinumab is known to be efficient in adult patients suffering from moderate to severe Crohn disease (CD) and ulcerative colitis (UC) resistant to anti-tumor necrosis factor-alpha (TNF-α). Here, we described the clinical course of treatment
Mounzer Koudsi, C. Martinez-Vinson, B. Pigneur, S. Willot, Djeddi Djamal, R. Enaud, J. Rebeuh, C. Dupont, A. Dabadie, V. Bertrand, J. Hugot, A. Lachaux, F. Ruemmele, J. Viala, R. Duclaux-Loras, Getaid Pédiatrique   +15 more
semanticscholar   +1 more source

A Randomized, Double-blind, Phase III Study Assessing Clinical Similarity of SB17 (Proposed Ustekinumab Biosimilar) to Reference Ustekinumab in Subjects with Moderate to Severe Plaque Psoriasis.

Journal of American Academy of Dermatology
BACKGROUND Ustekinumab is a safe and effective treatment for moderate-to-severe psoriasis. OBJECTIVES To compare efficacy, safety, pharmacokinetics (PK), and immunogenicity of the proposed ustekinumab biosimilar SB17 with reference ustekinumab (UST) in
Steven R. Feldman, Joanna Narbutt, G. Girolomoni, J. Brzezicki, N. Reznichenko, M. Zegadło-Mylik, Grażyna Pulka, Magdalena Dmowska-Stecewicz, Elżbieta Kłujszo, D. Rekalov, Lidia Rajzer, Jiyoon Lee, Minkyung Lee, Young Hee Rho   +13 more
semanticscholar   +1 more source